These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 26417913)

  • 1. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
    Han SO; Li S; Brooks ED; Masat E; Leborgne C; Banugaria S; Bird A; Mingozzi F; Waldmann H; Koeberl D
    Hum Gene Ther; 2015 Jan; 26(1):26-35. PubMed ID: 25382056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
    Han SO; Li S; Koeberl DD
    Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
    Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
    FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
    Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
    Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa
    Sellier P; Vidal P; Bertin B; Gicquel E; Bertil-Froidevaux E; Georger C; van Wittenberghe L; Miranda A; Daniele N; Richard I; Gross DA; Mingozzi F; Collaud F; Ronzitti G
    J Inherit Metab Dis; 2024 Jan; 47(1):119-134. PubMed ID: 37204237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
    Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
    Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
    Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
    Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
    Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
    Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.
    Sun B; Young SP; Li P; Di C; Brown T; Salva MZ; Li S; Bird A; Yan Z; Auten R; Hauschka SD; Koeberl DD
    Mol Ther; 2008 Aug; 16(8):1366-71. PubMed ID: 18560415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.
    Li S; Sun B; Nilsson MI; Bird A; Tarnopolsky MA; Thurberg BL; Bali D; Koeberl DD
    FASEB J; 2013 Jan; 27(1):34-44. PubMed ID: 22993195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.
    Cagin U; Puzzo F; Gomez MJ; Moya-Nilges M; Sellier P; Abad C; Van Wittenberghe L; Daniele N; Guerchet N; Gjata B; Collaud F; Charles S; Sola MS; Boyer O; Krijnse-Locker J; Ronzitti G; Colella P; Mingozzi F
    Mol Ther; 2020 Sep; 28(9):2056-2072. PubMed ID: 32526204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.